The N-Formyl Peptide Receptor 2 pipeline drugs market research report outlays comprehensive information on the N-Formyl Peptide Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the N-Formyl Peptide Receptor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Respiratory, and Immunology which include the indications Myocardial Infarction, Atherosclerosis, Alzheimer’s Disease, Multiple Sclerosis, Asthma, Acute Respiratory Distress Syndrome, Rheumatoid Arthritis, and Inflammation. It also reviews key players involved in N-Formyl Peptide Receptor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The N-Formyl Peptide Receptor 2 pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 5, 2, and 1 respectively.
N-Formyl Peptide Receptor 2 overview
N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated to regulate cell function by binding to a wide variety of ligands like N-Formylmethionine-containing oligopeptides such as N-Formylmethionine-leucyl-phenylalanine (FMLP), polyunsaturated fatty acid metabolite of arachidonic acid, lipoxin A4 (LXA4). FPR2 mediates responses to a wide range of polypeptides and proteins which may serve to promote inflammation.
For a complete picture of N-Formyl Peptide Receptor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
